Background. Oxidative stress has been linked to the progression of disease, including chronic kidney disease (CKD). The aim of the present study was to determine the association between single-nucleotide polymorphisms (SNPs) of the antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase and their activities and the progression of CKD. Methods. This is a prospective cohort study of 185 CKD patients (Stages 2-4), followed for up to 12 months. All patients were genotyped for SNPs of SOD (SOD Ala16Val), GPx (GPx Pro197Leu) and catalase (C-262T). The rate of change over the study period of estimated glomerular filtration rate (eGFR), plasma and red blood cell (RBC) GPx, RBC SOD and RBC catalase activities were determined. Results. CKD patients with the SOD Ala/Val and Val/Val genotypes had a significantly greater eGFR decline compared to those with the Ala/Ala genotype (Ala/Val compared with Ala/Ala odds ratio (OR) 0.35, 95% CI 0.19 to 0.64, P ¼ 0.001; Val/Val compared with Ala/Ala OR 0.25, 95% CI 0.10 to 0.65, P ¼ 0.005). The progression of CKD was not associated with SNPs of the GPx or catalase genes studied but there was a direct relationship between the rate of change of plasma GPx activity and the rate of change of eGFR over 12 months (P ¼ 0.025). Conclusion. CKD patients with the SOD Ala/Val and Val/ Val genotypes have a greater decline in kidney function than those with the Ala/Ala genotype.
Introduction
Oxidative stress has been linked to the progression of several diseases, including cancer [1] , diabetes [2] , Alzheimer's and other neurodegenerative diseases [3] , cardiovascular disease (CVD) [4] and chronic kidney disease (CKD) [5] . Oxidative stress results from increased concentrations of reactive oxygen species and/or a reduction in antioxidants. The antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase form the primary defence system against reactive species and oxidative stress [6] .
SOD converts superoxide (O 2À ) to hydrogen peroxide (H 2 O 2 ) and three isoforms have been identified. SOD1 (CuZnSOD) is present in red blood cells (RBCs), SOD2 (MnSOD) is primarily mitochondrial and SOD3 is extracellular [7] [8] [9] [10] . GPx is responsible for the conversion of H 2 O 2 and other organic peroxides, to water and oxygen [11] . Five isoforms of GPx have been identified, with two present in human blood: GPx 1 in RBC [12] and GPx 3 (eGPx), which is produced by the kidney, in plasma [13] . Catalase converts H 2 O 2 to water and oxygen and is present in all aerobic cells, with the highest levels in the liver, kidney and RBC [14] .
Single-nucleotide polymorphisms (SNPs) of antioxidant enzymes may contribute to diseases associated with oxidative stress. These include the SOD2 SNP, rs4880 Ala16Val genotype, that substitutes a C>T at position 2734 and changes the amino acid at position 16 from alanine (Ala) to valine (Val). A C>T mutation at amino acid position 197 in GPx 1 (noted in NCBI as position 200 and also reported at position 198) changes proline (Pro) to leucine (Leu). The catalase SNP, rs1001179, is a C>T substitution at position -262 from the transcription start site, a GC-rich area of the 5#-untranslated promoter region [15] .
These SNPs and changes in the activities of the respective enzymes have been associated with altered progression and/or risk of diseases, including breast cancer [16] , lung cancer [17] , diabetic neuropathy [18] and acute kidney injury [19] . Moreover, the links between the activities of antioxidant enzymes and CKD have been the subject of several case-control studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . However, to date, there have been no studies addressing the associations between antioxidant enzyme SNPs, antioxidant enzyme activities and the progression of CKD. Thus, the aims of the present study were to determine whether the progression of CKD, defined for this study as decline in eGFR over 1 year, was associated with (i) specific genotypes resulting from GPx, SOD and/or catalase SNPs and (ii) changes in GPx, SOD and/or catalase activities.
Materials and methods
The Human Research Ethics Committee (Tasmania) Network approved the study (H08618). All participants provided a written informed consent. Data collection commenced in March 2006 and was completed in May 2008.
Study subjects and design A prospective cohort study design was used. Participants with established CKD were recruited from the Launceston General Hospital, private practices in the Launceston and the North West Satellite Renal Unit (Burnie), Tasmania, Australia. The inclusion criteria were CKD with eGFR < 60 mL/min/1.73 m 2 , !18 years of age and a minimum of three samples collected over a 12-month period (>1 month apart) to determine the rates of change of eGFR and antioxidant activities.
Outcome measures
The primary outcome measures were rate of change of eGFR, SOD, GPx and catalase enzyme activities over 12 months of the three SOD, GPx and catalase genotypes.
Blood sampling and biochemical analysis
Venous blood, collected in plain and lithium heparin tubes, was centrifuged, serum and plasma separated and stored at À80°C for later analysis of serum creatinine and plasma GPx activity. RBC, prepared from lithium heparin tubes, were washed with 0.9% saline, lysed with distilled water [25] and stored at À80°C for later measurement of RBC GPx, SOD and catalase activities. Plasma and RBC GPx activities were measured on a DataPro Clinical Analyzer (Thermo-Electron, Melbourne, Australia) and RBC SOD and catalase on a Cobas Mira Clinical Analyser (Roche Laboratories, Rotkreuz, Switzerland). Commercially available kits (Randox Laboratories, Crumlin, Ireland) were used to measure plasma GPx, RBC GPx and RBC SOD activities. The inter-and intra-batch coefficients of variation (CVs) for plasma GPx were 6 and 10.2%, RBC GPx activity, 5.2 and 6.7% and SOD activity 4.6 and 5.7%, respectively. RBC catalase activity was measured using Slaughter's [26] methodology with interand intra-batch CVs of 1.8 and 5.3%, respectively. Serum creatinine was analysed using an Architect C8000 analyser (Abbott Diagnostics, North Ryde, Australia; Calibrator MC Cal Traceable to NIST SRM 909b-2). Measurements were made within 3 months of blood collection, and data used to calculate eGFR by the 
Statistical analysis
Hardy-Weinberg analysis was carried out on all genotype population groups. SOD and catalase genotypes for both controls and patients were within the Hardy-Weinberg equilibrium. Sample size calculation predicted that in order to detect a minimum 2-fold increase in the rate of decline of eGFR (0.15 mL/min/month to 0.3 mL/min/month), at least 37 homozygote mutation patients and 453 patients of other genotypes would be required; in order to detect a 2.4-fold increase of eGFR decline, 19 homozygote mutations and 231 patients of other genotypes would be required (assuming a standard deviation of change of 0.31 mL/min/month and a homozygote mutation frequency of 8%; alpha 0.05 and 1-beta 0.8).
While we aimed to recruit an even larger number of patients, only 261 patients were recruited during the study period. General linear modelling (GLM) was used to analyse all data where data were normally distributed and reported as mean difference. Ordinal logistic regression was used as a non-parametric alternative to GLM when skewness and heteroskedasticity of residuals indicated that assumptions of simple linear regression were violated and comparisons reported as odds ratio (OR). Multivariate analysis was performed using backward stepwise regression. When determining associations with either eGFR or antioxidant enzyme activities, age, gender, smoking status, change over time of all antioxidant activities, initial eGFR, initial antioxidant activities, antioxidant genotypes, primary cause of CKD and medications were presented for selection by stepwise regression for inclusion in the multivariate model. P-values were corrected for multiple comparisons using the Holm 
Results
Of the 269 patients recruited, 39 did not present to the pathology laboratory to provide a blood sample ( Figure 1 ). After the remaining 230 participants were genotyped, over the 12-month follow-up, 8 died, 3 commenced dialysis, 2 received kidney transplants and 32 provided insufficient samples to allow rate of change in eGFR and antioxidant activities to be calculated. Seventy-seven subjects provided three samples and 108 subjects provided four samples over the 12-month study period. Hence, 185 Caucasian CKD patients were genotyped (Table 2) . Baseline eGFR, rate of change of eGFR and baseline enzyme activities were measured for all 185 patients, whereas the rates of change of SOD, GPx and catalase activities could only be measured for 169 patients. The primary cause of renal disease was classified according to the criteria of the Australian and New Zealand Dialysis Transplant Registry (ANZDATA) [28] (Table 2) .
During the study, eGFR declined in 61%, increased in 24% and was stable in 15% of patients. Patients with the Ala/Val and Val/Val SOD genotypes had a more rapid decline in eGFR compared to the Ala/Ala genotype (Ala/Val compared with Ala/Ala OR 0.35, 95% CI 0.19 to 0.64; Val/Val compared with Ala/Ala OR 0.25, 95% CI 0.10 to 0.65) (Table 3, Figure 2A ). Furthermore, this effect persisted when adjusted for all measured confounding variables, with Ala/Val and Val/Val genotypes linked to a faster rate of eGFR decline (P ¼ 0.002; P ¼ 0.006, respectively) ( Table 4) .
Progression of CKD was not associated with GPx or catalase SNPs (Figure 2B and C; Table 3 ). For patients with the GPx Leu/Leu genotype, the rate of change in plasma GPx activity was significantly reduced compared with GPx Pro/Pro genotype (OR 0.42, 95% CI 0.20 to 0.87, P ¼ 0.02) but not the GPx Pro/Leu genotype. When adjusted for all confounding variables, the change in plasma GPx activity over the 12-month study period was significantly reduced in patients with the GPx Leu/Leu genotype (P ¼ 0.026) (Table 4) . However, no other changes in RBC GPx, RBC SOD and RBC catalase activities over time were influenced by any of the SNPs.
Univariate analysis suggested that changes in plasma GPx activity and eGFR over the 12-month study period were related (P ¼ 0.069) ( Figure 3A) . When all confounding variables were included in a multivariate analysis, a significant association between the decline in eGFR and plasma GPx activity over time was observed (P ¼ 0.025) (Table 4) , this being our best estimate of an independent effect. Conversely, the changes in RBC GPx (P ¼ 0.939), RBC SOD (P ¼ 0.079) and RBC catalase (P ¼ 0.992) activities were not associated with the change in eGFR over 12 months.
Patients with higher eGFR at entry into study (baseline) had a greater decline in kidney function over 12 months (P ¼ 0.046) ( Figure 3B ). However, baseline antioxidant enzyme activities did not influence the rate of decline of eGFR over the 12-month period. On the other hand, the rate of change of all four enzyme activities was inversely related to the activity of the individual enzyme at baseline (plasma GPx, RBC GPx and RBC catalase, P < 0.0001; RBC SOD, P ¼ 0.004) (see Figure 4A and B, for examples). This remained significant (P, all <0.0005) when adjusted for all confounding variables (Table 4) .
Changes in individual antioxidant activities were influenced by the baseline activity of other antioxidant enzymes. Higher baseline catalase activity was associated with increasing plasma GPx (P ¼ 0.017) over 12 months ( Figure 4C ). When multivariate analysis was performed, this association persisted (P ¼ 0.003) ( Table 4 ). In addition, higher baseline RBC GPx activity was associated with declining RBC catalase activity over 12 months (P < 0.0001). Finally, when adjusted for all confounding variables, there was a positive association between baseline SOD activity and catalase activity over the 12-month study period (P ¼ 0.017) ( Table 4 ). The rate of change in plasma GPx activity was inversely related to the change in RBC SOD activity (P ¼ 0.025; Table 3 ). However, when confounders were included, this relationship did not persist (Table 4 ). In contrast, RBC GPx was positively associated with SOD activity (P ¼ 0.004) and catalase activity with RBC GPx activity (P < 0.001) over 12 months (Table 3) . These associations persisted when data were subjected to multivariate analysis (Table 4) . CKD caused by type 1 diabetes mellitus (n ¼ 8, T1DM) was associated with an increase in RBC GPx activity over time (P ¼ 0.003, Table 4 ), whereas T2DM (n ¼ 32) was associated with a faster decline in SOD activity over time (P ¼ 0.008, Table 4 ). Table 3 Antioxidant enzyme genotypes and changes in kidney function and antioxidant enzymes (mean 6 SD)
SOD Ala16Val Genotypes
GPx Pro197Leu Genotypes Catalase C-262T Genotypes a These associations (OR) and 95% confident intervals (CIs) were estimated using ordinal logistic regression due to skewness and heteroskedasticity; with all continous variables standardized normal transformation. Variables for inclusion by stepwise regression were selected (if P < 0.2) from the following co-variants: demographic: age, gender, never smoked, given up smoking, still smoking; causes of CKD: uncertain, other, reflux nephropathy and analgesic nephropathy; medications: erythropoietin, anti-inflammatory and ace inhibitors. Variables marked with a dash were not included in the regression model of that particular outcome variable. Constant (not part of this analysis, but shown for illustrative purposes) is mean change of eGFR and the antioxidant activities when all other confounders were minimum or zero, estimated by general linear modelling. *P < 0.05, **P < 0.01 and ***P < 0.001.
Discussion
To our knowledge, this is the first study to investigate associations between antioxidant enzyme genotypes, their activities and the progression of CKD over a period of 12 months. The major findings were that (i) CKD patients with the SOD Ala/Val and Val/Val genotypes had significantly greater eGFR decline compared to patients with the Ala/Ala genotype and (ii) declining plasma GPx activity was associated with eGFR decline. The most significant finding was the accelerated eGFR decline in patients with either SOD Ala/Val or Val/Val genotypes. Why this polymorphism predisposes individuals to CKD is not clear. It has been suggested that the amino acid change from Ala to Val may have an effect on the structure of SOD, changing an alpha helix structure to a beta sheet [29] . Previous studies have suggested that the Ala allele is associated with higher SOD mitochondrial activity and may hence be more protective against oxidative stress and against progression of diseases that have been linked to oxidative stress, including CKD [30] . However, in the present study, the actual change in RBC SOD activity over 12 months was not influenced by genotype. This apparent disparity may relate to the SOD location or may suggest that the SOD SNP may be associated with another, yet to be identified, abnormality in CKD patients.
Another explanation for more rapid eGFR decline associated with the Val allele is co-existing vascular disease and diabetes (T1DM and T2DM), which were the primary cause of CKD in 22 and 37% of patients, respectively. In the present study, the Ala/Val and Val/Val SOD genotypes accounted for 78% of patients with CKD of vascular origin. Many studies (>70) have investigated the relationship between the SOD Ala16Val genotype and disease, including three relating to CVD [31] [32] [33] and seven to T1DM and T2DM [34] [35] [36] [37] [38] [39] . In particular, a large case-control study involving 989 participants (504 hypertensive, 485 controls) found a significant relationship between carotid artery intima-media thickness, and the Val allele in women that had high levels of low-density lipoprotein (LDL) cholesterol (P ¼ 0.03) [32] . Others have reported an increased risk of cardiomyopathy in haemochromatosis patients with Val allele compared with those with the Ala allele [33] , that the Ala/Val and Val/Val genotypes were associated with increased levels of oxidized LDL compared with Ala/Ala genotype in patients with oxidized LDL < 0.5 nmol/mg [31] , and an increased risk of diabetic nephropathy in T1DM patients with the SOD Val/Val genotype [37] . The frequency of the SOD Val/Val genotype was also found to be higher in T2DM patients with diabetic nephropathy [38] . The present study suggests a link between SOD Ala/Val and Val/Val genotypes and both CVD and diabetes, in addition to CKD.
Declining plasma GPx was positively associated with declining eGFR over 12 months, although this was independent of GPx genotype. As the kidney is the main source of production of plasma GPx, plasma GPx activity may follow decreasing production of GPx by the kidney as its function declines [13] . Case-control studies also reported a direct relationship between reduced plasma GPx activity and decreased kidney function in CKD patients [7, 20-23, 40, 41] . However, the majority of these studies involved 50 patients [20] [21] [22] [23] 40] or had limited numbers of controls (~30 healthy participants) [7, 41] . In contrast, the present study is the first to show a direct association between faster progression of CKD and lower plasma GPx over an extended time in a large cohort.
Declining eGFR over 12 months was associated with increasing RBC SOD activity. A case-control study by Ceballos-Picot et al. [7] reported that RBC SOD activity was unchanged in CKD, but there have been no other cohort studies. One possible explanation for the current finding might be the reduced life expectancy and reduced deformability of RBCs in subjects with declining kidney function [42, 43] . Mature erythrocytes are anucleate and protein synthesis is thought to take place during erythropoiesis [44] . Consequently, if a greater percentage of the RBC is younger in CKD patients, the amount of SOD present in RBC may be relatively high.
While the present studies suggest that high baseline antioxidant activities are associated with declining antioxidant activities over time, this may be a regression to the mean. Nevertheless, the interplay between baseline antioxidant activities and changes in other antioxidant activities demonstrates a direct link between the GPx and catalase activities. This conclusion is supported by the previously reported direct relationship between deficiency of glucose-6-phosphate dehydrogenase (G6PD), which maintains levels of glutathione, a substrate for GPx, and impaired catalase activity [45] .
Our overall findings regarding SOD and RBC GPx activities contrast with those of Karajibani et al. [46] who reported no significant association between RBC SOD and RBC GPx activities in 71 CVD patients and 63 healthy controls. Thus, the present study suggests a link between RBC antioxidant activities in CKD that has not been reported in CVD.
There are a number of factors that may limit the findings of this study. The study was underpowered due to the small sample size. All CKD patients available in the Northern Tasmanian population were recruited. A larger study population and an extended study time are recommended in subsequent studies to strengthen the antioxidant genotype findings (particularly as the number of GPx Leu/Leu genotypes was so low). In addition, this study population was entirely Caucasian, and future investigations should include other ethnicities. Calculating eGFR using MDRD from serum creatinine has its limitations as a measure of kidney function, compared with radioisotopic methods, which are impractical because of costs and logistics. Although still based on serum creatinine, the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) may in the future provide a more accurate estimate of kidney function but since we excluded patients with eGFR >60 mL/min/1.73 m 2 , the MDRD equation should be sufficient [47, 48] . Finally, measurement of other enzymes and cofactors involved the pathways (e.g. G6PD and glutathione) and other measures of oxidative stress such as malondialdehyde and F2 isoprostanes would provide a more complete picture of antioxidant status in CKD.
To conclude, we measured antioxidant genotypes at baseline and followed antioxidant enzyme activity and kidney function in 185 CKD patients over 12 months. Patients with the SOD Val/Val or Ala/Val genotypes had a greater decline in kidney function, suggesting that SOD genotypes may be used to identify CKD patients at risk of more rapid CKD progression. Tailoring of treatment, including antioxidant therapies, might be investigated to determine whether they slow progression of CKD [49] . Similarly, as a more rapid decline in kidney function is associated with decreasing plasma GPx activity, assessment of the effects of enhancing the activity of GPx could be worthy of further investigation.
